title: [Treatment of hepatitis B surface antigen (HBsAg)-positive chronic hepatitis with recombinant alpha-A-interferon. Results of a phase II study].
abstract: The HBsAg carrier state may present as chronic active hepatitis which may proceed to cirrhosis of the liver and to primary liver cell carcinoma. The large scale production of interferons made these substances available for long-term treatment. A deficiency in interferon production in chronic type B hepatitis presented the rational to treat this disease with interferon alpha-A. In this phase II-trial 3/31 patients eliminated HBsAg and 14/31 HBeAg. This was followed by normalisation of liver function tests and probably an improved prognosis. Efficiency of treatment was dependent on the interferon dose, the level of viral replication, the level of liver enzymes before treatment and concurrent infections (e. g. HIV infection). Reactivation occurred in five patients suggesting that the treatment period was too short in some individuals. Future studies will potentially improve efficiency by the modification of the interferon schedule and a better understanding of the mode of action of interferon.
authors.affiliation: I. Medizinische Klinik, Johannes-Gutenberg-Universität Mainz.
authors.forename: G
authors.initials: G
authors.lastname: Hess
authors.forename: C
authors.initials: C
authors.lastname: Weber
authors.forename: S
authors.initials: S
authors.lastname: Rossol
authors.forename: R
authors.initials: R
authors.lastname: Voth
authors.forename: N
authors.initials: N
authors.lastname: Drees
authors.forename: K H
authors.initials: KH
authors.lastname: Meyer zum Büschenfelde
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006513:Hepatitis B e Antigens / Q000032:analysis; D006521:Hepatitis, Chronic / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*
chemical_list: D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007370:Interferon Type I; D011994:Recombinant Proteins
vernacular_title: Behandlung der Hepatitis-B-Surface-Antigen(HBsAg)-positiven chronischen Hepatitis mit rekombinantem alpha-A-Interferon. Ergebnisse einer Phase-II-Studie.